JP2018509903A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018509903A5 JP2018509903A5 JP2017547468A JP2017547468A JP2018509903A5 JP 2018509903 A5 JP2018509903 A5 JP 2018509903A5 JP 2017547468 A JP2017547468 A JP 2017547468A JP 2017547468 A JP2017547468 A JP 2017547468A JP 2018509903 A5 JP2018509903 A5 JP 2018509903A5
- Authority
- JP
- Japan
- Prior art keywords
- antisense oligonucleotide
- mrna
- oligonucleotide
- nucleotides
- antisense
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021131294A JP7188810B2 (ja) | 2015-03-11 | 2021-08-11 | 表皮水疱症治療のためのｃｏｌ７ａ１エクソン７３とマッチするオリゴヌクレオチド |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1504124.7A GB201504124D0 (en) | 2015-03-11 | 2015-03-11 | Oligonucleotides |
| GB1504124.7 | 2015-03-11 | ||
| PCT/EP2016/055360 WO2016142538A1 (en) | 2015-03-11 | 2016-03-11 | Oligonucleotides matching col7a1 exon 73 for epidermolysis bullosa therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021131294A Division JP7188810B2 (ja) | 2015-03-11 | 2021-08-11 | 表皮水疱症治療のためのｃｏｌ７ａ１エクソン７３とマッチするオリゴヌクレオチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018509903A JP2018509903A (ja) | 2018-04-12 |
| JP2018509903A5 true JP2018509903A5 (enExample) | 2019-04-18 |
| JP6929783B2 JP6929783B2 (ja) | 2021-09-01 |
Family
ID=52998751
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017547468A Expired - Fee Related JP6929783B2 (ja) | 2015-03-11 | 2016-03-11 | 表皮水疱症治療のためのｃｏｌ７ａ１エクソン７３とマッチするオリゴヌクレオチド |
| JP2021131294A Active JP7188810B2 (ja) | 2015-03-11 | 2021-08-11 | 表皮水疱症治療のためのｃｏｌ７ａ１エクソン７３とマッチするオリゴヌクレオチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021131294A Active JP7188810B2 (ja) | 2015-03-11 | 2021-08-11 | 表皮水疱症治療のためのｃｏｌ７ａ１エクソン７３とマッチするオリゴヌクレオチド |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10563198B2 (enExample) |
| EP (2) | EP3763816A1 (enExample) |
| JP (2) | JP6929783B2 (enExample) |
| KR (1) | KR20170120617A (enExample) |
| CN (1) | CN107567498B (enExample) |
| AU (1) | AU2016231067B2 (enExample) |
| BR (1) | BR112017019225A2 (enExample) |
| CA (1) | CA2978375A1 (enExample) |
| DK (1) | DK3268474T3 (enExample) |
| EA (1) | EA035732B1 (enExample) |
| ES (1) | ES2803651T3 (enExample) |
| GB (1) | GB201504124D0 (enExample) |
| HR (1) | HRP20200944T1 (enExample) |
| HU (1) | HUE050898T2 (enExample) |
| IL (1) | IL254173B (enExample) |
| MX (2) | MX384959B (enExample) |
| PL (1) | PL3268474T3 (enExample) |
| PT (1) | PT3268474T (enExample) |
| SI (1) | SI3268474T1 (enExample) |
| WO (1) | WO2016142538A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA50829A (fr) * | 2015-06-01 | 2018-04-11 | Sarepta Therapeutics Inc | Exclusion d'exon induite pat technologie antisens dans le collagène de type vii |
| EP3744333A4 (en) | 2018-01-25 | 2021-11-03 | Osaka University | MEDICAL COMPOSITION FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AN INCREASE IN THE LEVEL OF EXPRESSION OF PERIOSTIN OR A CHANGE IN THE SPLICE VARIANT THEREOF |
| GB201902735D0 (en) | 2019-02-28 | 2019-04-17 | Proqr Therapeutics Ii Bv | Oligonucleotides for use in the treatment of dystrophic epidermolysis bullosa |
| AU2020395113A1 (en) | 2019-12-02 | 2022-06-09 | Shape Therapeutics Inc. | Therapeutic editing |
| US20240110181A1 (en) * | 2020-12-10 | 2024-04-04 | Institut National de la Santé et de la Recherche Médicale | Substances and methods for treating dystrophic epidermolysis bullosa |
| EP4609882A1 (en) * | 2022-10-12 | 2025-09-03 | CPC Corporation | Gene introduction method, gene therapy method, and tissue regeneration method |
| CN116555349A (zh) * | 2023-01-09 | 2023-08-08 | 中吉智药(南京)生物技术有限公司 | 一种腺相关病毒载体及其构建方法与应用 |
| CN118001404B (zh) * | 2024-02-06 | 2025-02-25 | 四川大学华西医院 | 抑制C17orf67基因表达试剂在制备治疗获得性大疱表皮松解症药物中的用途 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US7101993B1 (en) | 1990-01-11 | 2006-09-05 | Isis Pharmaceuticals, Inc. | Oligonucleotides containing 2′-O-modified purines |
| US5952221A (en) | 1996-03-06 | 1999-09-14 | Avigen, Inc. | Adeno-associated virus vectors comprising a first and second nucleic acid sequence |
| JP2000508922A (ja) | 1996-04-26 | 2000-07-18 | ケース ウエスターン リザーブ ユニバーシティ | 間葉幹細胞を用いる皮膚再生 |
| JP2002080662A (ja) | 2000-09-08 | 2002-03-19 | Jsr Corp | ゴム組成物 |
| EP1191097A1 (en) | 2000-09-21 | 2002-03-27 | Leids Universitair Medisch Centrum | Induction of exon skipping in eukaryotic cells |
| EP2221376B1 (en) | 2001-06-21 | 2012-11-21 | Isis Pharmaceuticals, Inc. | Antisense modulation of superoxide dismutase 1, soluble expression |
| US20030147968A1 (en) | 2001-12-19 | 2003-08-07 | Alwyn Company, Inc. | Allantoin-containing preparations for administration as gels and aerosols |
| US20040096833A1 (en) | 2002-11-16 | 2004-05-20 | Isis Pharmaceuticals Inc. | Modulation of FBP-interacting repressor expression |
| US20040092464A1 (en) | 2002-11-11 | 2004-05-13 | Isis Pharmaceuticals Inc. | Modulation of mitogen-activated protein kinase kinase kinase 11 expression |
| DE10238298A1 (de) | 2002-08-21 | 2004-03-04 | Beiersdorf Ag | Verwendung von Antisense-Oligonucleotiden zur Behandlung von degenerativen Hauterscheinungen |
| AU2003225410A1 (en) | 2003-03-21 | 2004-10-11 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
| US8765169B2 (en) | 2004-02-13 | 2014-07-01 | Smith & Nephew, Inc. | Wound healing profile |
| US20080207538A1 (en) | 2004-03-11 | 2008-08-28 | Lawrence David S | Enhanced Production of Functional Proteins From Defective Genes |
| EP2933332A1 (en) | 2004-06-28 | 2015-10-21 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
| GB0505202D0 (en) | 2005-03-14 | 2005-04-20 | Intercytex Ltd | Skin equivalent culture |
| WO2007069813A1 (en) | 2005-12-16 | 2007-06-21 | Modern Cell & Tissue Technologies Inc. | Methods for culturing mesenchymal stem cell and compositions comprising mesenchymal stem cell for reparing skin defects |
| EP1991677A2 (en) | 2006-01-26 | 2008-11-19 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to huntingtin |
| EP1857548A1 (en) * | 2006-05-19 | 2007-11-21 | Academisch Ziekenhuis Leiden | Means and method for inducing exon-skipping |
| SI2049664T1 (sl) | 2006-08-11 | 2012-04-30 | Prosensa Technologies Bv | Enojna veriga oligonukleotidov, komplementarna repetitivnim elementom, za zdravljenje genetskih bolezni, povezanih z nestabilnostjo dnk ponovitev |
| WO2008106984A2 (en) | 2007-03-07 | 2008-09-12 | Aarhus Universitet | Pig model for breast cancer, mitochondria related protein folding disorders and/or epidermolysis bullosa simplex |
| US8077297B2 (en) | 2008-06-30 | 2011-12-13 | Nellcor Puritan Bennett Ireland | Methods and systems for discriminating bands in scalograms |
| EP2151248A1 (en) | 2008-07-30 | 2010-02-10 | Johann Bauer | Improved pre-mRNA trans-splicing molecule (RTM) molecules and their uses |
| EP2601294B1 (en) | 2010-08-05 | 2018-11-28 | Academisch Ziekenhuis Leiden h.o.d.n. LUMC | Antisense oligonucleotide directed removal of proteolytic cleavage sites from proteins |
| EP2672977A1 (en) * | 2011-02-08 | 2013-12-18 | The Charlotte-Mecklenburg Hospital Authority d/b/a Carolina Healthcare System | Antisense oligonucleotides |
| US9603949B2 (en) * | 2011-09-01 | 2017-03-28 | University Of Iowa Research Foundation | Oligonucleotide-based probes for detection of bacterial nucleases |
| KR20140091688A (ko) * | 2011-10-06 | 2014-07-22 | 미라젠 세러퓨틱스 인코포레이티드 | 마이크로rna 조절에 의한 전신 에너지 항상성의 제어 |
| ES2670495T3 (es) * | 2011-10-11 | 2018-05-30 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Tratamiento de salto de exones para epidermólisis ampollosa distrófica |
| HK1205707A1 (en) | 2012-03-07 | 2015-12-24 | Fibrocell Technologies, Inc. | Topical dermal formulations and methods of personalized treatment of skin |
| US20150141320A1 (en) | 2012-05-16 | 2015-05-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating gene expression |
| EP3019610B2 (en) | 2013-07-08 | 2025-03-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for performing antisense oligonucleotide-mediated exon skipping in the retina of a subject in need thereof |
| DK3220924T3 (da) | 2014-11-17 | 2022-01-03 | Rev Pharma Corp | Lægemiddel til topisk anvendelse til hud- og slimhindeskader i forbindelse med epidermolysis bullosa |
| MA50829A (fr) | 2015-06-01 | 2018-04-11 | Sarepta Therapeutics Inc | Exclusion d'exon induite pat technologie antisens dans le collagène de type vii |
| LT3307277T (lt) | 2015-06-15 | 2020-12-28 | Tirmed Pharma Ab | Viengrandžiai oligonukleotidai, skirti naudoti mediciniškai gydant odos sutrikimus |
| WO2017078526A2 (en) | 2015-11-05 | 2017-05-11 | Rijksuniversiteit Groningen | Antisense oligonucleotide-mediated exon skipping as systemic therapy for recessive dystrophic epidermolysis bullosa (rdeb). |
-
2015
- 2015-03-11 GB GBGB1504124.7A patent/GB201504124D0/en not_active Ceased
-
2016
- 2016-03-11 US US15/554,420 patent/US10563198B2/en active Active
- 2016-03-11 MX MX2017011599A patent/MX384959B/es unknown
- 2016-03-11 PL PL16709465T patent/PL3268474T3/pl unknown
- 2016-03-11 JP JP2017547468A patent/JP6929783B2/ja not_active Expired - Fee Related
- 2016-03-11 WO PCT/EP2016/055360 patent/WO2016142538A1/en not_active Ceased
- 2016-03-11 EA EA201791986A patent/EA035732B1/ru unknown
- 2016-03-11 DK DK16709465.5T patent/DK3268474T3/da active
- 2016-03-11 CA CA2978375A patent/CA2978375A1/en active Pending
- 2016-03-11 AU AU2016231067A patent/AU2016231067B2/en not_active Ceased
- 2016-03-11 CN CN201680015142.2A patent/CN107567498B/zh not_active Expired - Fee Related
- 2016-03-11 KR KR1020177025038A patent/KR20170120617A/ko not_active Abandoned
- 2016-03-11 HU HUE16709465A patent/HUE050898T2/hu unknown
- 2016-03-11 HR HRP20200944TT patent/HRP20200944T1/hr unknown
- 2016-03-11 SI SI201630794T patent/SI3268474T1/sl unknown
- 2016-03-11 BR BR112017019225-0A patent/BR112017019225A2/pt not_active Application Discontinuation
- 2016-03-11 ES ES16709465T patent/ES2803651T3/es active Active
- 2016-03-11 EP EP20175344.9A patent/EP3763816A1/en not_active Withdrawn
- 2016-03-11 EP EP16709465.5A patent/EP3268474B1/en active Active
- 2016-03-11 PT PT167094655T patent/PT3268474T/pt unknown
-
2017
- 2017-08-27 IL IL254173A patent/IL254173B/en unknown
- 2017-09-08 MX MX2021009135A patent/MX2021009135A/es unknown
-
2020
- 2020-01-17 US US16/746,403 patent/US11352626B2/en active Active
-
2021
- 2021-08-11 JP JP2021131294A patent/JP7188810B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018509903A5 (enExample) | ||
| JP2017079776A5 (enExample) | ||
| DK3222724T3 (en) | ADDITIONALLY UNKNOWN FORMS OF INTERFERRING RNA MOLECULES | |
| Kraynack et al. | Small interfering RNAs containing full 2′-O-methylribonucleotide-modified sense strands display Argonaute2/eIF2C2-dependent activity | |
| Lee et al. | Antisense technology in molecular and cellular bioengineering | |
| Kumar et al. | Gene manipulation through the use of small interfering RNA (siRNA): from in vitro to in vivo applications | |
| JP2009524419A5 (enExample) | ||
| JP2016518331A5 (enExample) | ||
| JP2015523855A5 (enExample) | ||
| EP2021507A4 (en) | COMPOSITIONS AND METHODS FOR INHIBITING PCSK9 GENE EXPRESSION | |
| JP2015523853A5 (enExample) | ||
| CN104955950A (zh) | 具有改善的脱靶特征谱的寡核苷酸 | |
| JP2018513668A5 (enExample) | ||
| JP2014527401A5 (enExample) | ||
| JP2009536827A5 (enExample) | ||
| WO2009102427A3 (en) | Modified rnai polynucleotides and uses thereof | |
| JP2015518714A5 (enExample) | ||
| JP2010530239A5 (enExample) | ||
| JP2009513144A5 (enExample) | ||
| JP2016522674A5 (enExample) | ||
| JP2018507711A5 (enExample) | ||
| WO2008147824A3 (en) | Hydroxymethyl substituted rna oligonucleotides and rna complexes | |
| JP2012029693A5 (enExample) | ||
| WO2007112753A8 (en) | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides | |
| JP2013510561A5 (enExample) |